Index - P/E - EPS (ttm) -1.11 Insider Own 23.13% Shs Outstand 36.83M Perf Week 24.44%
Market Cap 132.83M Forward P/E - EPS next Y -0.85 Insider Trans 82.45% Shs Float 30.85M Perf Month 43.29%
Income -56.83M PEG - EPS next Q -0.30 Inst Own 56.21% Short Float 0.79% Perf Quarter 215.24%
Sales 0.00M P/S - EPS this Y -10.89% Inst Trans -0.33% Short Ratio 0.72 Perf Half Y 222.93%
Book/sh 2.31 P/B 1.43 EPS next Y 24.49% ROA -45.04% Short Interest 0.24M Perf Year 53.95%
Cash/sh 2.31 P/C 1.43 EPS next 5Y - ROE -48.79% 52W Range 0.72 - 3.69 Perf YTD 233.50%
Dividend Est. - P/FCF - EPS past 5Y 48.08% ROI -60.65% 52W High -10.30% Beta 1.22
Dividend TTM - Quick Ratio 12.00 Sales past 5Y 0.00% Gross Margin - 52W Low 359.72% ATR (14) 0.32
Dividend Ex-Date - Current Ratio 12.00 EPS Y/Y TTM 21.54% Oper. Margin 0.00% RSI (14) 64.31 Volatility 9.91% 12.03%
Employees 51 Debt/Eq 0.03 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 9.67
Option/Short No / Yes LT Debt/Eq 0.02 EPS Q/Q -2.62% Payout - Rel Volume 1.00 Prev Close 2.97
Sales Surprise - EPS Surprise 10.98% Sales Q/Q - Earnings Feb 13 AMC Avg Volume 336.17K Price 3.31
SMA20 15.88% SMA50 43.61% SMA200 127.10% Trades
Volume 335,677 Change 11.45%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-09-24 Initiated Maxim Group
Buy
$8
Aug-02-22 Resumed Canaccord Genuity
Buy
$17
Jun-15-22 Initiated Cantor Fitzgerald
Overweight
$9
Sep-08-21 Initiated ROTH Capital
Buy
$21
May-27-21 Initiated Oppenheimer
Outperform
$25
May-25-21 Initiated H.C. Wainwright
Buy
$21
Apr-23-24 08:00AM
Mar-20-24 02:33PM
Mar-06-24 07:30AM
Feb-13-24 04:05PM
Jan-24-24 08:00AM
08:00AM
Loading…
Jan-23-24 08:00AM
Dec-14-23 08:00AM
Dec-13-23 08:00AM
Nov-24-23 11:14AM
Nov-17-23 08:00AM
Nov-13-23 04:05PM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
Sep-14-23 04:05PM
Sep-06-23 07:00AM
04:05PM
Loading…
Jun-27-23 04:05PM
Jun-01-23 12:45PM
May-11-23 04:05PM
Mar-23-23 04:50PM
Mar-08-23 07:00AM
Feb-10-23 04:05PM
Dec-15-22 07:00AM
Nov-09-22 04:05PM
Nov-01-22 07:00AM
Oct-20-22 07:00AM
Sep-15-22 04:05PM
Sep-07-22 07:00AM
Aug-15-22 08:36AM
Jun-01-22 07:00AM
May-12-22 04:05PM
04:01PM
Loading…
May-04-22 04:01PM
09:33AM
May-01-22 11:25PM
02:00PM
Apr-26-22 04:05PM
Mar-29-22 07:00AM
Mar-23-22 07:00AM
Feb-22-22 07:00AM
Feb-09-22 04:05PM
Nov-12-21 04:05PM
Oct-19-21 12:14PM
Oct-13-21 08:10AM
Oct-12-21 04:05PM
Sep-22-21 04:05PM
Sep-15-21 04:56PM
Sep-09-21 04:05PM
Sep-07-21 04:05PM
Aug-10-21 07:00AM
Aug-03-21 07:00AM
Jun-28-21 07:00AM
Jun-24-21 09:01PM
Jun-03-21 05:35AM
May-31-21 10:17AM
May-27-21 07:00AM
May-20-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
07:00AM
May-04-21 08:00AM
Apr-19-21 08:00AM
Mar-22-21 08:00AM
Mar-08-21 08:00AM
Mar-02-21 05:16PM
Feb-10-21 04:05PM
Jan-12-21 08:30AM
Jan-11-21 07:56AM
Dec-28-20 04:05PM
Dec-03-20 08:00AM
Nov-19-20 08:00AM
Nov-05-20 08:00AM
Oct-09-20 08:30AM
Sep-10-20 08:00AM
Jul-27-20 08:00AM
Jun-15-20 08:30AM
May-28-20 08:30AM
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBERTS BRIAN KENNETH Chief Medical Officer Mar 28 '24 Buy 2.55 500 1,275 1,076 Mar 29 11:08 AM Evans Daron CFO Mar 15 '24 Buy 1.69 20,000 33,830 20,000 Mar 19 09:17 AM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 14 '24 Buy 1.88 10,000 18,800 10,000 Mar 18 11:20 AM Evans Daron CFO Mar 08 '24 Buy 1.93 50,000 96,345 120,900 Mar 08 12:37 PM Kim Young-Jin Director Mar 07 '24 Buy 1.91 36,503 69,859 115,450 Mar 14 10:35 AM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 07 '24 Buy 1.85 500 925 500 Mar 11 10:35 AM Elam Nevan C CEO Feb 26 '24 Buy 1.68 5,000 8,400 7,817 Feb 28 11:40 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 26 '24 Buy 1.70 2,000 3,400 42,552 Feb 27 08:47 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 23 '24 Buy 1.69 6,000 10,140 40,552 Feb 27 08:47 AM Evans Daron CFO Feb 16 '24 Buy 1.30 41,900 54,411 70,900 Feb 20 07:01 AM Evans Daron CFO Feb 16 '24 Buy 1.37 9,000 12,330 4,500 Feb 20 07:01 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 16 '24 Buy 1.31 7,000 9,142 34,552 Feb 21 11:55 AM ROBERTS BRIAN KENNETH Chief Medical Officer Jul 03 '23 Buy 1.90 5,000 9,500 27,552 Jul 06 11:18 AM
Index RUT P/E - EPS (ttm) -0.33 Insider Own 51.14% Shs Outstand 138.14M Perf Week 6.69%
Market Cap 650.00M Forward P/E - EPS next Y -0.38 Insider Trans -0.27% Shs Float 67.50M Perf Month 2.06%
Income -54.70M PEG - EPS next Q -0.10 Inst Own 42.33% Short Float 4.96% Perf Quarter -2.99%
Sales 0.00M P/S - EPS this Y -17.75% Inst Trans 2.91% Short Ratio 3.79 Perf Half Y 28.90%
Book/sh 1.02 P/B 4.63 EPS next Y 3.49% ROA -34.47% Short Interest 3.35M Perf Year 148.94%
Cash/sh 1.17 P/C 4.00 EPS next 5Y - ROE -44.08% 52W Range 1.83 - 5.70 Perf YTD 0.11%
Dividend Est. - P/FCF - EPS past 5Y 29.09% ROI -32.76% 52W High -17.46% Beta 0.74
Dividend TTM - Quick Ratio 15.66 Sales past 5Y -20.00% Gross Margin - 52W Low 157.10% ATR (14) 0.28
Dividend Ex-Date - Current Ratio 15.66 EPS Y/Y TTM -33.96% Oper. Margin 0.00% RSI (14) 48.73 Volatility 6.62% 6.29%
Employees 37 Debt/Eq 0.19 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 8.79
Option/Short Yes / Yes LT Debt/Eq 0.19 EPS Q/Q -32.79% Payout - Rel Volume 0.71 Prev Close 4.68
Sales Surprise - EPS Surprise 12.88% Sales Q/Q - Earnings Mar 07 AMC Avg Volume 884.48K Price 4.70
SMA20 -1.55% SMA50 -4.13% SMA200 11.89% Trades
Volume 630,571 Change 0.53%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated Guggenheim
Buy
$7
May-16-23 Upgrade Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade Jefferies
Buy → Hold
$2
Mar-16-21 Initiated Piper Sandler
Overweight
$7
Mar-15-21 Initiated Oppenheimer
Outperform
$4
Jun-13-19 Reiterated H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed ROTH Capital
Neutral
$12
Jan-03-18 Initiated Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed ROTH Capital
Buy
$40
Sep-22-17 Initiated Jefferies
Buy
$20
Sep-11-17 Initiated JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
08:05AM
Loading…
Feb-02-24 08:05AM
Jan-31-24 08:05AM
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
07:29PM
Loading…
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
04:05PM
Loading…
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Jan-19-23 06:43AM
Jan-18-23 06:28AM
Jan-17-23 06:27AM
Jan-13-23 06:56AM
Jan-12-23 06:50AM
Jan-11-23 06:53AM
Jan-09-23 06:31AM
Jan-06-23 06:49AM
Jan-05-23 05:43AM
Jan-04-23 06:54AM
06:54AM
Jan-03-23 06:26AM
Dec-30-22 07:17AM
Dec-29-22 06:51AM
Dec-27-22 07:11AM
Dec-23-22 06:32AM
Nov-22-22 04:05PM
Nov-10-22 04:05PM
Nov-09-22 04:05PM
Sep-14-22 04:05PM
Sep-06-22 04:05PM
Sep-03-22 08:16AM
Sep-01-22 08:05AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM Chang Carmen 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:07 PM Behbahani Ali 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:06 PM BASKETT FOREST 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:05 PM Growth Equity Opportunities 17 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:04 PM Yang Rick 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:13 PM SANDELL SCOTT D 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:11 PM Walker Paul Edward 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:12 PM Mathers Edward T 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:10 PM Makhzoumi Mohamad 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:09 PM Florence Anthony A. Jr. 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:08 PM Pratt Raymond Dennis Chief Medical Officer Jun 26 '23 Buy 2.93 6,500 19,045 160,000 Jun 27 07:00 AM RAMSAY DAVID A Director May 26 '23 Buy 2.63 37,124 97,599 2,201,142 May 26 11:31 AM RAMSAY DAVID A Director May 25 '23 Buy 2.57 12,876 33,130 2,164,018 May 26 11:31 AM RAMSAY DAVID A Director May 24 '23 Buy 2.56 50,000 127,800 2,151,142 May 26 11:31 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
